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Platinum chemotherapy remains part of standard therapies in the management of a variety of cancers.
Severe side effects and a high degree of resistance to platinumdrugs have led numerous researchers to search
for predictive biomarkers, which could aid in identifying patients that are the most likely to respond to
therapy. The ERCC1-ERCC4 endonuclease plays a critical role in the repair of platinum-DNA damage and
has widely been studied in relation to sensitivity to platinum chemotherapy. The standard method to
evaluate ERCC1 protein expression is through the use of immunohistochemistry withmonoclonal antibody
8F1, an antibody that was recently found to bind an unrelated protein. The present study determines the
specificity of a novel antibody, monoclonal antibody 4F9, and presents a method to evaluate ERCC1
expression in colorectal tumor specimens. Using relevant cell lines as controls, the specificity of antibody
4F9was tested by immunoblotting, immunohistochemistry and immunofluorescence. Scoring guidelines to
aid in the evaluation of ERCC1 tumor expression were developed and evaluated in archival formalin-fixed
paraffin embedded colorectal cancer specimens. Antibody 4F9 was found to be specific by all methods
applied and it was possible to evaluate the ERCC1 expression in the majority (85%) of colorectal cancer
tumor specimens.
T
he identification of molecular markers that can help guide treatment decisions in cancer is central to
improving the therapeutic index of the current arsenal of chemotherapeutic drugs. Platinum drugs, such
as cisplatin and oxaliplatin, are part of standard chemotherapy regimens in several cancer types, including
non-small cell lung cancer (NSCLC) and colorectal cancer (CRC). CRC is one of the leading causes of cancer
death, accounting for approximately 8% of total cancer deaths worldwide1. In metastatic CRC, response rates to
oxaliplatin-based chemotherapy are as low as 34%2. Therefore, to improve upon patient survival and quality of
life, the identification of a predictive biomarker profile for platinum-based chemotherapy is essential, so that only
patients that are likely to respond receive platinum chemotherapy.
Oxaliplatin and other platinum compounds inhibit tumor cell proliferation and induce cell death due to the
formation of intracellular platinum-DNA adducts. These adducts consist of platinum-DNA monoadducts,
platinum-DNA intra- and interstrand crosslinks, as well as DNA-protein crosslinks3,4. Platinum-DNA mono-
adducts and intrastrand crosslinks can be processed and repaired by nucleotide excision repair (NER)5.
Interstrand crosslinks (ICL) are repaired through the activation of ICL repair, which involves several repair
systems, such as homologous recombination, translesion synthesis, as well as NER6. The ERCC1-ERCC4 (XPF)
heterodimer plays a critical role as a structure-specific endonuclease involved in both NER and ICL repair7,8,
making it an interesting target for study in relation to platinum sensitivity/resistance.
A possible link between ERCC1 and platinum sensitivity has been investigated in a variety of cancer types9–16.
Several studies using immunohistochemistry (IHC) to evaluate ERCC1 protein expression have relied on the use
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of anti-ERCC1 monoclonal antibody clone 8F1. This particular anti-
body has been found to cross-react with an unrelated protein17,18 and
recent evidence suggests altered antibody specificity19. Taken
together, the evidence supporting or opposing the use of ERCC1
protein expression in tailoring chemotherapy cannot be relied upon.
Novel anti-ERCC1 antibodies have recently been developed, includ-
ing antibody 4F918, but before these can be used, thorough validation
is required.
Inspired by the approach undertaken by Bhagwat et al.17, the pur-
pose of the current study was to validate anti-ERCC1 antibody 4F9,
allowing us and others to investigate the role of ERCC1 in relation to
platinum sensitivity/resistance. To validate this antibody, we evalu-
ated the specificity of antibody 4F9 and examined its use in IHC,
where the influence of pre-analytical factors such as tissue fixation
duration wasmapped. Finally, the antibody was used in tumor speci-
mens from a stage III CRC cohort, where oxaliplatin remains part of
standard treatments, to test its ability to determine varying levels of
ERCC1 expression in patient tumors, and therefore also its ability to
potentially aid in clinical decision making.
Results
Testing the specificity of antibody 4F9. For the detection of a pro-
tein of interest, ensuring antibody specificity is of paramount impor-
tance. The specificity of antibody 4F9 was assayed by western blot in
protein lysates from cell lines Colo-205 and XP2YO. Antibody 4F9
produced a single and strong band corresponding to the molecular
weight of ERCC1 (approximately 37 to 38 kDa) in Colo-205,
whereas a relatively weak band was observed in XP2YO (Fig. 1A).
In paraffin-embedded Colo-205 and XP2YO cells stained with
antibody 4F9, strong nuclear expression of ERCC1 was observed in
Colo-205 (see Fig. 1C). In XP2YO, weak cytoplasmic staining was
observed, along with an absence of expression in the majority of
nuclei.
To further evaluate the specificity of antibody 4F9, the detection of
ERCC1 at sites of oxaliplatin-induced DNA damage was assayed by
immunofluorescence in Colo-205 cells. Untreated cells showed little
or no c-H2AX signal generation and relatively uniform ERCC1
expression in nuclei (Fig. 1D). In oxaliplatin-treated cells, large c-
H2AX foci were observed with similarly large co-localized ERCC1
foci. Western blot of Colo-205 lysates from treated and untreated
cultures (Fig. 1B) confirmed the presence of c-H2AX in oxaliplatin-
treated cells only.
To confirm that antibody 4F9 reacts with the reported epitope, a
peptide containing the epitope (AEYAISQ) was constructed and pre-
incubated with antibody 4F9 prior to IHC staining. As shown in
Fig. 1E, without the peptide, antibody 4F9 stained tonsil germinal
center cells in a variety of intensities. Upon inhibition with the pep-
tide at 1 mgml21, the observed staining intensities decreased substan-
tially. Complete inhibition was achieved with 10 mgml21 peptide,
where no staining was observed. Antibody 4F9 was also tested by
an enzyme-linked immunosorbent assay (ELISA) against a random
peptide or a peptide representing the 4F9 epitope (see supplementary
note 4). Above-background absorbance was only detected in wells
containing the 4F9 epitope (see fig. S2).
Identification of references and effect of fixation. To evaluate the
expression levels of ERCC1 in tumor cells, where the observed
staining intensity may be affected by pre-analytical and analytical
factors, we sought to identify relevant tissues that express the protein,
so that these tissues could be used as an external reference. Tonsil
tissue appeared to stain in an easily recognizable pattern (see Fig. 1E)
and was selected as an external reference. A single tonsil specimen
was studied and staining intensities of various cell populations were
graded on a scale from 0 to 3 corresponding to none (0), low (1),
moderate (2) and high (3) staining intensity by two investigators.
Fibroblasts scored 0 and 1, whereas endothelial cells scored 0, 1 and 2.
The mantle zone surrounding the germinal center scored predo-
minately 0 and 1, while the germinal center generally stained 1 and
2, unidentified cell populations (consisting of numerous cell types,
including macrophages and centroblasts) scattered throughout the
germinal center scored 3 (see Fig. 1E). The squamous epithelium
harbored cells of all staining intensities, with stronger intensities
observed closer to the basal layer. These observations did not vary
among tonsils tested (see supplementary note 3).
To identify relevant internal IHC scoring references in colorectal
tissue, numerous tissue specimens were stained and screened for
easily recognizable non-cancerous cells, which appeared to stain
similarly across samples (data not shown). This screening resulted
in the identification of parasympathetic ganglion cells (Meissner and
Auerbach’s plexuses) and epithelial cells lining the colorectal crypts
as potential references. Ganglion cells generally showed high intens-
ity ERCC1-specific staining, whereas crypt epithelial cells exhibited
relatively low intensity staining. To determine whether the staining
intensity of these cell types was affected by fixation time, small sec-
tions from 19 different tumors were allocated to receive 6, 24, 48 and
168 h fixation in NBF (CRC fixation time study), resulting in a total
of 228 sections. These sections were stained and compared to a tonsil
tissue reference (Fig. S1). Ganglion cells were present in 94 tissue
sections from a total of 228 (41.2%). Amedian of 5 observations were
made per tumor (range: 1–10) with amedian of 23.5 observations per
fixation time (range: 23–25). As shown in Fig. 2, the staining intensity
of these cells decreased at longer fixation times, specifically with a
decreasing proportion of samples harboring ganglion cells with an
intensity score of 3 at longer fixation times (100% and 6 h, 89.0% at
24 h, 78.2% at 48 h and 63.6% at 168 h). A test of association
between the staining intensity of ganglion cells and tissue fixation
time revealed a significant interaction (Cochran-Mantel-Haenzel
test, p 5 0.002, after adjusting for which of the original 19 tumors
the section stemmed from). The highest staining intensity observed
in ganglion cells was therefore chosen as an internal reference for the
high (3) ERCC1 expression category (see Fig. 3).
The colorectal crypt epithelium was present in 65 (28.5%) tissue
sections. Amedian of 4 observations per tumor (range: 0–6) and 16.5
observations per fixation time (range: 13–19) weremade. Themajor-
ity of cells scored as follows: 0 and 1 (50.0%) or 0, 1 and 2 (38.9%)
following 6 h fixation (see Fig. 2). The staining intensity of these cells
decreased at longer fixation times, specifically an increasing fraction
of crypt epithelial cells scoring 0 and 1 were observed (73.7% at 24 h,
100% at 48 h and 168 h). A test of association between the staining
intensity of these cells and tissue fixation time revealed a significant
interaction (Cochran-Mantel-Haenzel test, p5 0.007, after adjusting
for tumor of origin). The weakest positive staining intensity observed
in crypt epithelial cells was therefore chosen to reflect the low (1)
ERCC1 expression category (Fig. 3).
Formulation of scoring system and training study. To determine
the feasibility of using the previously identified internal references to
assign staining intensities in CRC tumor samples, 50 FFPE CRC
tumor samples were stained and studied (referred to as training
study, see table 1). Ganglion cells were observed in 92% (46/50) of
specimens. The majority of ganglion cells stained with either high
(3), or moderate and high (2 and 3) intensity relative to relevant cells
in a tonsil reference. Colorectal crypt epithelium was present in 96%
(48/50) of samples and mostly contained cells with no or low
intensity staining (see table S3). Both references were present in
90% (45/50) of samples.
Prior to final formulation of the IHC scoring system, intrasection
tumor heterogeneity was investigated. To allow for limited fluc-
tuation in ERCC1 expression, homogeneity was defined as the dif-
ference in staining intensities being no greater than ‘1’.
By this definition, 11.1% (5/45) of samples were categorized as
heterogeneous. Two patterns of heterogeneity were observed. The
www.nature.com/scientificreports
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first pattern was defined as heterogeneity present in the entire tumor
section, whereas the second pattern was due to the presence of two
distinct tumor components, indicatingmultiple clones. Regardless of
type, the highest staining intensity observed in .5% tumor cells
was noted for each tumor, as well as whether the expression was
homogenous or heterogeneous in tumor cells (see fig. 4 for final
formulation of scoring system). Scoring of tumor cells by using the
aforementioned internal references categorized the majority (71.1%)
of tumor specimens as low (1) (see Table 2). As shown in Table 1,
ERCC1 expression was not associated with tumor stage. ERCC1
Figure 1 | Testing the specificity of anti-ERCC1 antibody 4F9. (A) Cropped western blot of protein lysates from Colo-205 and XP2YO. (B) Cropped
western blot of protein lysates from Colo-205 with and without 8 mM oxaliplatin. (C) Immunohistochemical staining of paraffin-embedded Colo-205
and XP2YO cells. (D) Detection of ERCC1 and c-H2AX in Colo-205 chamber slide cultures by immunofluorescence. (E) Immunohistochemical staining
of parallel tonsil sections in presence and absence of peptide corresponding to the antibody 4F9 epitope. A germinal center in the absence (left) and
presence of epitope peptide at 1 mgml21 (middle) and 10 mgml21 (right).
Figure 2 | Graphical representations of results from fixation study. Comparisons between selected cell populations with an external tonsil reference.
www.nature.com/scientificreports
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expression was not significantly associated with tumor localization
(Fisher’s test, p 5 0.06), although 10 of 11 (90.9%) higher scoring
(scores: 2 and 3) tumors originated from the colon.
ERCC1 expression in pilot study. To investigate whether antibody
4F9 could potentially be used in a clinical decision making, a pilot
study was performed by evaluating ERCC1 expression in tumor
specimens from a stage III CRC cohort. At this disease stage (stage
III), oxaliplatin-based chemotherapy is part of standard regimens. A
total of 141 tumor specimens were stained. Internal references were
absent in 9 samples (6.4%) and in 12 samples (8.5%) staining was too
weak, indicative of extensive fixation. Immunostaining and scoring
was therefore successful for 120 samples (85.1%). Initially, the two
observers were in agreement in 97 of 120 cases (or 80.3%, weighted
kappa 5 0.75, 95% CI: 0.66–0.84). The majority of discordant cases
(13 out of 23 cases - 56.5%) were scored as 3 by at least one observer.
When staining intensity was considered as a binary variable (0, 1
versus 2, 3), interobserver agreement was 91.7% (110 of 120 cases,
kappa5 0.83, 95% CI: 0.73–0.93). As shown in Table 2, the majority
of samples could be categorized as ERCC1 low (46.7%) or ERCC1
moderate (35.0%) (see Fig. 3 for an example). The median value of
ERCC1 IHC scores was 1 in this cohort. ERCC1 expression was not
significantly associated with patient age, gender or tumor location
(see Table 1). Tumor heterogeneity was observed in 21 (17.5%)
specimens.
Discussion
Specificity.The predictive value of ERCC1 expression inNSCLCwas
initially demonstrated in a study conducted by Olaussen and collea-
gues9. Patients with ERCC1-negative tumors appeared to benefit
from adjuvant cisplatin-based chemotherapy, whereas those with
ERCC1-positive tumors gained no benefit. In this initial study,
antibody 8F1 appeared to bind ERCC1 specifically27. Subsequent
research revealed that this antibody binds ERCC1, as well as an
unrelated protein, namely PCYT1A18,17. Efforts to reproduce these
Figure 3 | Immunohistochemical staining of a stage III CRC tumor specimen. (A): Ganglion cells. (B): Tumor cells. (C): Crypt epithelium. The applied
scoring guidelines require a comparison of tumor cells (B) with ganglion cells (strongest intensity is reference for score 3) (A) and crypt epithelium
(weakest intensity is reference for score 1) (C). The tumor consists of cells producing staining intensities similar to ganglion cells, as well as cells that stain
weaker, but stronger than crypt epithelium (i.e. moderate). Therefore, the final score of this tumor was 2–3, which was reported as ‘ERCC1 high –
homogenous’.
Table 1 | Clinicopathlogic characteristics of patients included in the present study
Patient Cohort Frequency (%) Association with ERCC1 expression
Training study Stage I 7 (15.6) 0.4a
II 25 (55.6)
III 13 (28.9)
Location Colon 29 (64.4) 0.06a
Rectum 16 (35.6)
Pilot study Median (range)
Age 68 (33–85) 20.08, p 5 0.38b
Frequency (%)
Gender Male 73 (60.8) 0.30a
Female 47 (39.2)
Stage III 120 (100) -
Location Colon 62 (51.7) 0.15a
Rectum 58 (48.3)
ap-value from fisher’s exact test.
bspearman’s rank correlation.
www.nature.com/scientificreports
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initial findings using the original specimens have failed19. For that
reason, we hypothesize that at some time between the original
NSCLC study in 20069 and the first report of cross-reactivity of
8F1 in 200917, the specificity of antibody 8F1 was altered. Although
these results are published, antibody 8F1 remains the most widely
used anti-ERCC1 to date with continued use in 201328–30. This use
continues to shed uncertainty on published findings related to
ERCC1 and highlights the need for a novel ERCC1-specific antibody.
To ensure that antibody 4F9 is specific, a three pronged approach
was undertaken in the present study: firstly, specificity for size and
location was tested in immunoblots of lysates from Colo-205 and
XP2YO. XP2YO was selected as a control for low ERCC1 expression
as cell lines without any functional ERCC1 are very difficult to main-
tain in culture31. XP2YO harbors several mutations in the ERCC4
gene, which cause ERCC4 expression to be particularly low in this
cell line17,32,33. Interestingly, ERCC1 is rapidly degraded unless the
protein is in complex with ERCC434, making XP2YO a relevant
choice as a low expression control for ERCC1-specific antibodies.
In the current study, antibody 4F9 detected substantial ERCC1 in
Colo-205, while ERCC1 was detected at markedly lower levels in
XP2YO. Secondly, specificity for functionality (ERCC1 DNA repair
activity) and localization was tested by immunofluorescence. Due to
its involvement in the processing and removal of DNA damage, the
ERCC1-ERCC4 heterodimer should co-localize to sites of platinum-
induced double strand DNA breaks, measured here by c-H2AX
phosphorylation8. In the present study, antibody 4F9 correctly gen-
erated signals for ERCC1 at double strand DNA breaks, indicating
specificity and supporting the use of antibody 4F9 in biomarker
investigations related to oxaliplatin. Finally, to confirm the specificity
of antibody 4F9 to its reported epitope, the interaction between
antibody and peptide was tested by IHC inhibition and ELISA.
This revealed that antibody 4F9 binds this epitope in a concentra-
tion-dependent manner. These results are in line with those iden-
tified by Friboulet and colleagues19. It should be noted that this amino
acid sequence is present in ERCC1 isoforms 201, 202, 203, but not
204. Taken together, these findings suggest that antibody 4F9 binds
ERCC1 specifically, a result which is in line with those previously
reported18.
Scoring guidelines. During tissue fixation, formalin reacts with a
variety of biological end groups, forming hydroxymethyl adducts.
These adducts react with other end groups, forming (methylene)
crosslinks between proteins, thereby preserving protein localization
and tissue morphology, as well as inactivating factors that may cause
tissue degradation (reviewed in35). Crosslink formation is reversible
by antigen retrieving tissue pretreatment. The extent of crosslink for-
mation is related to tissue fixation time, which is often unknown in
archival material and practices may vary from institution to
institution, making it a pre-analytical factor which can be highly
variable in archival material from multicenter studies. If antibody
4F9 is to be used in IHC, the effects of fixation time must be
elucidated and practical scoring guidelines must be created.
When subjected to longer fixation periods, the ERCC1-specific
staining intensity of particular cell populations in colorectal tissue
Figure 4 | ERCC1 IHC Scoring System.
Table 2 | ERCC1 expression in the two cohorts analyzed in the
present study
IHC Score
Frequency (%)
Training study Pilot study
0 2 (4.4) 6 (5.00)
1 32 (71.1) 56 (46.7)
2 8 (17.8) 42 (35.0)
3 3 (6.7) 16 (13.3)
www.nature.com/scientificreports
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appeared to decrease significantly. This finding raised the require-
ment of identifying relevant internal staining references, which could
compensate for the fixation-dependent decrease in the observed
ERCC1-specific staining intensity. Ganglion cells and cells of the
crypt epithelium stained with higher intensities following 6 h fixa-
tion than at longer fixation periods. While fixation time may vary
day-to-day and institution-to-institution, we hypothesized that 24 to
48 h was most representative fixation period for archival tumor
material. Interestingly, this fixation time-dependence does not
appear to only affect 4F9 staining, but also that other anti-ERCC1
antibodies, such as 8F1, 8K105, 2E12, FL297 and SMP243 (unpub-
lished data). It should be noted that additional factors, such as tissue
ischemia time and tumor volume, may also influence the staining
intensity observed by IHC, but these were not investigated. Using the
findings of the fixation study, we chose to select ganglion cells (high-
est intensity) and the crypt epithelium (weakest positive intensity) as
references for the high (3) and low (1) ERCC1 expression categories,
respectively (see Fig. 3). The biological rationale for relatively high
ERCC1 expression in ganglion cells may be related to protection
from DNA damage36. It is unknown whether the expression of
ERCC1 in colorectal crypts is affected by exogenous factors. It should
be noted that similar staining intensities were observed in both the 19
tumor fixation material and the training study, suggesting limited
exogenous influence on ERCC1 expression. Through the use of these
references, we have designed a dynamic scoring system which can
compensate for a variety of tissue fixation times, but optimized for 24
to 48 h fixation.
We have in the current study chosen to record the relative express-
ion level of tumor cells without accounting for the proportion of
tumors cells with each expression level, e.g. by a semi-quantitative
H-score. This decision was made to ensure that the scoring system is
both practical and simple. Furthermore, we hypothesized that even a
minor component of tumor cells with high ERCC1 expression may
form the basis for tumor recurrence following oxaliplatin-based
chemotherapy. This hypothesis can only be tested in material from
patients that have undergone relevant chemotherapy and therefore
the adaptation of an H-score may be appropriate to investigate a
predictive effect of ERCC1 expression in relation to oxaliplatin-based
chemotherapy.
In the present study, a scoring system was developed to evaluate
ERCC1 expression in full sections fromCRC tumors. The selection of
colorectal crypt epithelial and ganglion cells as internal references
limits the usability of the scoring system in specimens that do not
contain these cell types, such as biopsies. Therefore, efforts to develop
biopsy-specific references, or valid external controls, are warranted.
ERCC1 tumor expression. To determine whether antibody 4F9
could be used to distinguish between different levels of ERCC1
expression in archival material, CRC tumor specimens from two
cohorts were evaluated. These were selected because they are
representative of patients that would undergo platinum-based
chemotherapy today. Tissue references were present in the
majority of samples from both CRC cohorts, and the staining
intensity was acceptable in 100 and 91.5% in cohorts 1 and 2,
respectively. In both cohorts, the largest fraction of tumors
expressed low levels of ERCC1. Interestingly, a higher percentage
of tumors scored 2 and 3 in the pilot study cohort (48.3%) when
compared to the training cohort (24.4%). This finding could not be
attributed due to higher tumor stage, as no association was found
between protein expression and patient clinicopathological
characteristics in the training study (see Table 1).
In the pilot study, interobserver agreement was acceptable
(80.3%). Interestingly, the major source of disagreement was related
to the high expression category (score 3). This disagreement could be
circumvented by applying a binarized version of the scoring system,
where tumor specimens can be assigned to either a positive (scores 2,
3) or negative (scores 0, 1) ERCC1 expression level category. While
this improves interobserver agreement in the present study, it also
limits the resolution of the scoring system in detecting differences in
ERCC1 expression. A higher resolution may be crucial in future
investigations into the possible link between ERCC1 expression
and patient outcome following platinum-based chemotherapy.
Recent evidence suggests that only ERCC1 isoform 202 is respons-
ible for the removal of cisplatin-adducts19. Due to a high degree of
homology between isoforms, it is not possible to produce antibodies
specific for only the 202 isoform. Therefore, whether ERCC1
expression, specifically isoforms 201, 202 and 203, is related to out-
come following platinum-based chemotherapy remains to be
studied. It should be noted that low ERCC1 mRNA expression (all
isoforms) has previously been shown to be linked to benefit from
oxaliplatin in advanced CRC10,19. Furthermore, clarification of the
exact roles of each of the four ERCC1 isoforms in the repair oxali-
platin-inducedDNAdamage inCRC is required.We plan on investi-
gating ERCC1 as a predictive biomarker for likely outcome following
oxaliplatin-based chemotherapy in metastatic CRC through the use
of antibody 4F9 in IHC, as well as by fluorescent in situ hybridization.
We have previously studied ERCC1 gene copy number alterations in
tumor specimens from the patient of the pilot study37. There appears
to be a significant correlation between ERCC1 gene copy number and
ERCC1 protein expression (see supplementary note 1, table S4),
suggesting that this may be in fact be the underlying mechanism
for ERCC1 overexpression. With both these assays, we hope to shed
light on the link between ERCC1 and platinum-based chemotherapy.
In conclusion, the current study highlights the necessity of anti-
body validation before investigational use in archival tumormaterial.
While antibody 4F9 was found to be specific, a fixation time-depend-
ent decrease in staining intensity was observed in IHC. To counter
this, CRC-specific internal IHC staining references were identified
and successfully applied. Taken together, the validation of antibody
4F9 will allow us and others to confidently investigate the effects of
ERCC1 protein expression in relation to patient outcome following
oxaliplatin-based chemotherapy in CRC.
Methods
Cell lines. The CRC cell line Colo-205 was obtained from the NCI/Development
Therapeutics Program and was propagated in complete media: RPMI 1640
(Invitrogen) with 10% fetal bovine serum (Invitrogen). The transformed ERCC1-
deficient human fibroblast cell line XP2YO, an immortalized fibroblast cell line
stemming from a xeroderma pigmentosum complementation group F patient20, was
obtained from Coriell Cell Repositories and was cultured in complete media: DMEM
(Invitrogen) with 10% fetal bovine serum (Invitrogen).
Patient material. Tonsils.A total of six fresh tonsils were collected at the Department
of Pathology, A˚lborg University. Tonsils were trimmed and cut into two sections.
Each section was allocated to receive either 6 or 30 hour fixation in 10% neutral
buffered formalin (NBF). All tonsil specimens were completely anonymized prior to
receipt. According to the Danish law on the Research Ethics Committee System and
handling of biomedical research, as well as communication between Dako and the
Danish Committee on Biomedical Research Ethics and the Regional Ethics
Committee (IRB), the tests performed on tonsil specimens are not subject to an
approval by the IRB system because such studies are considered quality control
projects. Therefore, no IRB approval was obtained for the use of these specimens.
CRC tissue fixation study. A total of 19 fresh resected primary CRC tumors were
collected at the Department of Pathology, Odense University Hospital between
August 1995 and October 1996 (described in detail in21). Briefly, tumors were
trimmed for normal intestinal tissue and cut into parallel sections. For each tumor,
two sections were chosen by random systematic sampling and cut into approximately
2 mm parallel tissue chips, which were subsequently allocated to receive approxi-
mately 6, 24, 48 and 168 hours (1 week) fixation in NBF. Following fixation, tissue
chips were embedded in paraffin and new paraffin blocks were created containing
three tissue chips for each fixation time and tumor, resulting in two blocks per tumor.
Tumor specimens were completely anonymized prior to receipt. Similar to tonsil
specimens, this work can be considered a quality control project. Therefore, no IRB
approval was obtained for the use of these specimens.
CRC cohort 1: training study. Histologically proven stage I to III CRC specimens for
the training study were acquired from the Colorectal Cancer Follow-up (C-FUP)
study22. The C-FUP trial included 597 patients intended curative surgery for CRC
www.nature.com/scientificreports
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from January 1983 to June 1994. Fifty primary tumor specimens were randomly
selected from patients enrolled in group 1 (see22). The C-FUP trial was conducted in
accordance to Helsinki II Declaration and was approved by the Regional Ethical
Committee for the Counties of Vejle and Funen and the Danish Data Protection
Agency. Informed consent was obtained from all subjects. The exact duration of
fixation was not registered, but ranged from 12 hours to 1 week.
CRC cohort 2: pilot study. A total of 154 patients with histologically proven stage III
adenocarcinomas were selected as previously described23–25. FFPE primary tumor
specimens containing sufficient tumor cells were available for 141 (91.6%) patients.
As part of the RANX05 trial, patients were randomized to receive Ranitidine or
placebo for up to five years, as adjuvant chemo- and/or radiotherapy as this was not
part of the standard CRC treatment in Denmark at the time (1991–1993). Ranitidine
had no effect on survival26. All participants provided written informed consent. The
RANX05 trial was conducted in accordance with the Helsinki II Declaration and was
approved by the Danish National Board of Health, Data Protection Agency and
Central National Ethics Committee.
Immunoblotting. Cells were cultured in the presence and absence of oxaliplatin
(Fresenius Kabi) at a final concentration at 8 mM for 24 hours (see supplementary
note 2). Ten mg total protein from cell lines Colo-205 andXP2YOwere boiled (5 min)
in 63 loading buffer. Anti-ERCC1 antibody antibody 4F9 (Dako) was diluted 15500
(1.0 mgml21). Anti-c-H2AX (Clone PA1-25001, Thermo Scientific), detecting
histone H2AX phosphorylated at serine 139 (a marker for DNA double strand
breaks), was diluted 15500. As a protein loading control, anti-b-actin (clone AC-15,
Abcam) was applied at a dilution of 151000. For visualization, the Amersham ECL
Select Western Blotting Detection Reagent kit (GE Healthcare) was used.
Immunofluorescence. For immunofluorescence, cells were seeded in chamber slides
(Nunc) and allowed to plate for 72–96 h. Cells were then treated with or without
oxaliplatin (Fresenius Kabi) at a final concentration at 8 mM for 24 h (see
supplementary note 2). Staining was performed using an Autostainer instrument
(Dako). Briefly, cells were permeabilized by incubation with PBS containing 0.25%
Triton X-100 (10 min) and thereafter blocked with 10% goat serum in PBS for 1 hour.
Slides were treated with peroxidase block (5 min), and then incubated with a
polyclonal anti-c-H2AX rabbit antibody (dilution 151200) for 20 min to detect DNA
double strand breaks. Signal was generated by use of goat anti-rabbit secondary
antibody coupled to HRP (20 min) (Dako) with a Texas Red-based fluorescent
tyramide substrate (3 min) (Dako). To terminate signal generation, slides were
treated with peroxidase block. Slides were subsequently incubated with anti-ERCC1
antibody 4F9 at 1.66 mgml21 (corresponding to a dilution of 15300) for 20 min.
Antibody 4F9 was visualized by use of goat anti-mouse secondary antibody coupled
toHRPwith a FITC-based fluorescent tyramide substrate (3 min). Finally, slides were
washed and counterstained with DAPI and mounted.
Immunohistochemistry. Immunohistochemical staining. For immunostaining of
paraffin embedded cell lines (see supplementary note 2) and FFPE patient specimens,
all reagents came from the EnVisionTM FLEX, High pH kit (K8010) (Dako). Antigen
retrieval was performed at pH 9 for 20 min using a PT Link module (Dako). Staining
was performed in an Autostainer instrument (Dako) or manually according to
manufacturer’s instructions. Briefly, slides were treated with peroxidase block
(5 min), then incubated with anti-ERCC1 antibody 4F9 at 1.66 mgml21 for 20 min.
Visualization of antibody binding was done by incubation with a labeled HRP-
polymer for 20 min and signal was generated with a 3.39-diaminabenzidin (DAB)
chromogen (10 min). Hematoxylin was used for counterstaining.
IHC inhibition. A peptide containing the antibody 4F9 epitope (AEYAISQ, sequence
provided by Origene) (PolyPeptide Laboratories) was pre-incubated with antibody
4F9 at varying concentrations (overnight, 4uC). Slides were subsequently stained as
previously described.
Microscopical analysis. Tonsil and CRC fixation specimens were evaluated by two
investigators (AMK and JPH) simultaneously. Only nuclear ERCC1 staining was
considered. Only the nuclear staining intensity of relevant cell types was recorded by
comparison to a tonsil reference. Training study CRC specimens were scored by both
investigators individually. Discordant cases were reviewed and agreement was
reached. For the stage III CRC material, both investigators were unaware of clinical
data. Cases without internal references or extremely weak staining of references were
excluded.
Statistics. SAS versions 9.1 and 9.2 (SAS Institute, Cary, USA) were used to perform
all statistics. The association between fixation time and staining intensity of relevant
cell types was investigated by use of the Cochran-Mantel-Haenzel test, adjusting for
tumor of origin. Interobserver agreement was measured by concordance (calculated
by concordant cases/total cases) and by kappa statistics. Association between ERCC1
expression and clinicopathological characteristics was investigated by Fisher’s test.
All calculated p-values were considered significant at 0.05.
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